Monday, July 18, 2016

Get your lead list!
Have you written Banner term in the last 48 months?
Cell & Coffe bilss vs. Life Insurance costs
 
 
Banner has, for a limited-time, created an exchange program that gives existing customers the option to swap policies and re-start term coverage for another 25 years!

 
Click below for more information on the program!
 


 or 
 
 
 
Give us a call today at 800-842-8289 
 
 
Peter J. Zinnen, CLTC |  Senior Vice President - Operations
The Thompson Agency, Inc. |  www.thompsonagency.net
800.842.8289 ext. 300 | Local: 860.693.4999 | Fax: 860.693.4547 | Cell: 860.214.1639 

 
 
Having trouble viewing this email? Click here
If you no longer wish to receive our emails, click the link below:
Unsubscribe
The Thompson Agency 85 River Rd Collinsville, Connecticut 06019 United States (800) 842-8289

Delivered By Infusionsoft

Wednesday, May 11, 2016

Ulcerative Colitis | Facts & Case Studies




What is Ulcerative Colitis?

 

Ulcerative colitis, which is the most common type of inflammatory bowel disease, is a condition of episodic inflammation of the lining, or mucosa, of the colon, resulting in bloody diarrhea. The other type of inflammatory bowel disease is Crohn’s disease.

The cause of ulcerative colitis is unknown, but both environmental and genetic factors are thought to have a role. The condition is more common in North America and Northern Europe than in other parts of the world. The risk of ulcerative colitis is increased if there is a family history of inflammatory bowel disease.

Ulcerative colitis is less common in smokers and smokers who have ulcerative colitis tend to have mild disease. Having had an appendectomy at a young age decreases the risk of developing   ulcerative colitis. The inflammation in ulcerative colitis is felt to possibly be due to an immune response against the bacteria that normally live in the colon. The inflammation usually starts at the rectum, which is the end of the colon, and it can extend in a continuous manner to involve more areas and possibly the entire colon.

If the inflammation of ulcerative colitis only involves the rectum it is called ulcerative proctitis . If the rectum and the adjacent area, which is known as the sigmoid colon, are involved, it is called proctosigmoiditis. If the inflammation is more extensive but still limited to the left side of the colon that is known as left-sided colitis. Involvement of more than the left side of the colon is referred to as pancolitis.

It is possible that over time the inflammation may spread to areas of the colon that were not involved at the time of diagnosis. Ulcerative colitis does not affect the small intestine, except for occasional involvement of the ileum, which is located adjacent to the colon.

Besides bloody diarrhea, attacks of ulcerative colitis might cause abdominal pain, weight loss, anemia, passage of mucus, and fever. Most people will have periods of relapse and remission. In addition, ulcerative colitis may have manifestations outside of the colon, possibly causing arthritis, skin and mouth lesions, inflammation of the eyes, and liver disease.

 

Treatment

 

A number of medications may be used in the treatment of ulcerative colitis. The aminosalicylates, which include mesalamine, olsalazine, sulfasalazine, and balsalazide, are often the medication of choice both to achieve and to maintain remission.

Glucocorticoids may be used to achieve remission when aminosalicylates are not adequate, but are not effective in the maintenance of remission. The immunosuppressive agents azathioprine or 6-mercaptopurine might be prescribed in order to avoid the use of glucocorticoids, which can cause a number of serious side effects, including elevated glucose, osteoporosis, thinning of the skin, weight gain, cataracts, and several others.

Other medications that might be used in serious cases of ulcerative colitis include the immunosuppressive agents cyclosporine and tacrolimus, and the biologic agents, such as infliximab and adalimumab.

Up to about 30 percent of people with ulcerative colitis will ultimately require surgery, either due to failure of medical treatment or to complications. Removal of the entire colon (total colectomy) can cure the colonic manifestations of ulcerative colitis. However, total colectomy may not affect the risk or severity of ulcerative colitis associated liver disease.

 

Risk Factors

 

People with ulcerative colitis have an increased risk of colorectal cancer beginning about eight years after diagnosis, and thus periodic colonoscopy with biopsies to look for dysplasia or cancer is important. The cancer risk is related to the duration of disease and the extent of the colon involvement.

 

Underwriting Ulcerative Colitis

 

The underwriter considers a number of factors when evaluating applicants with ulcerative colitis, including current status, the extent of colon involvement, time since diagnosis, treatments prescribed, complications, and results of colonoscopy.

 

Case Studies

 

Applicant 1 was diagnosed with ulcerative colitis five years ago, with disease limited to the proctosigmoid area. No treatment has been necessary for the past three years, and a recent colonoscopy was normal. This case can be Standard Plus.

Applicant 2 has had pancolitis for fifteen years with associated arthritis, is taking azathioprine, and recently had a benign colonoscopy with biopsies. This case can be Table Three off of a Standard Plus base rate.

Applicant 3 has had ulcerative colitis for ten years. A recent colonoscopy showed three areas of dysplasia. Complete removal of the colon has been recommended, which the applicant is   considering. The dysplasia is premalignant and no offer can be made at this time. If the colon is removed reconsideration can be given based upon review of the pathology report. This case is a decline.


Let's have a look at your challenging Life Insurance Case


Don't Forget the Tax Advantages of Whole Life Insurance




Monday, April 25, 2016

Rheumatoid Arthritis | Facts & Cases

Characteristics

Rheumatoid arthritis is an autoimmune disease of unknown cause that results in chronic systemic inflammation affecting many parts of the body, but primarily the joints. The clinical course is highly variable. The disease can fluctuate and may sometimes go into remission for months or years, either spontaneously or with the use of various medications. After 10 years, about 20% of those affected will have no disability or joint deformities. Most however experience a progressive course with exacerbations and remissions associated with some loss of functioning. About 5-15% of affected individuals will have persistent disease activity throughout the course of this illness.

Symptoms

The disease process causes inflammation of the capsule around the joints, eventually leading in some cases to destruction of articular cartillage and fusion of the joints. While it usually involves smaller joints on both sides of the body, resulting in painful swelling and stiffness, it can also affect the larger joints. Likewise, in about 15-25% of cases the diffuse inflammation can involve the lungs, heart, kidneys, eyes, skin, nerves and blood vessels. About 1% of the population has rheumatoid arthritis, and women are two to three times more likely to have the disease than men. The onset can occur at any age, but it usually presents between the ages of 25 and 50. Rheumatoid arthritis becomes more prevalent at older ages.

Diagnosis & Treatments

Diagnosis is clinical and based on symptoms, physical exam, X-rays and serologic testing. There is no cure for rheumatoid arthritis, but many different treatments can improve symptoms and slow progression of the disease. Disease-modifying anti-rheumatic drugs (DMARDs) are the primary treatment. Started early in the course of the disease, these drugs produce remissions in about 50% of individuals. They generally improve symptoms, decrease joint damage and improve overall functional capacity.

Examples include methotrexate, sulfasalazine, leflunomide and hydroxychloroquine. Biologic agents may be part of the regimen. Examples include TNF blockers, interleukin 1 blockers and monoclonal antibodies. Non-steroidal anti-inflammatory agents can relieve symptoms but do not impact the course of the disease. Steroids can provide short term relief, but are generally avoided for long term use due to side effects.

Prognosis

Rheumatoid arthritis can reduce expectation of life by approximately 3 to 12 years. Higher mortality risk is associated with a younger age at onset, a longer duration of disease, concurrent presence of other health problems, and characteristics of more severe and progressive disease. The most common causes of death are cardiovascular disease, cancer and infection. Again, the underlying unifying pathology is generalized severe ongoing inflammation. Some of the more effective treatments for this disease may also have serious side-effects that contribute to its mortality.

Case Studies

APPLICANT 1
A 62 year old woman who was diagnosed with rheumatoid arthritis about 10 years ago. She is currently working full-time and plays golf once a week. She has occasional joint discomfort that responds to ibuprofen, and has required no other treatment. This can be Standard Plus.

APPLICANT 2
A 55 year old year old woman who has had rhematoid arthritis for several years. She is active in her community and participates in several volunteer organizations. She is limited by occasional diffuse joint pain and stiffness that have improved considerably with the use of methotrexate and a biologic agent. This can be Table 2.

APPLICANT 3
A 58 year old man who has been unable to work for the past three years due to severely deformed joints resulting from rheumatoid arthritis that began in his early 20s. He has undergone several joint replacements as well as cervical spine surgery for instability due to rheumatic involvement. He has recently experienced increasing shortness of breath, and his physician has been unable to determine whether his lungs have been affected by rheumatoid arthritis, its treatment with methotrexate, or perhaps both. This would be a decline.


Tuesday, December 1, 2015

We Did It, that is YOU Did It! Thank You!



We did it! ,...thanks to you!

Thank you to all those who helped us reach our goal in our efforts to fight Cancer!

Check out our results or donate here:  


https://www.no-shave.org/team/TeamThompson&thankyou=true
 
#GivingTuesday
 

— with Peter Zinnen, Frank Thompson, Brian Thompson and Adam Thompson.

Monday, November 16, 2015

And the Winner is...


At The BIG I Conference last week we met with many of our new and existing Independent Agency Partners. Our drawing was for a $100 donation, in the name of the winner, to Team Thompson’s No-Shave November Fund-raiser to benefit the Battle Against Cancer.

As promised, the winner was drawn today, and the winner is Carmen MacArthur, Insurance Service Rep at the HAI Group in Cheshire, CT.

Congratulations, Carmen, and thanks to all of you who visited our booth expressing support for us and our efforts in championing this amazing cause. 

Visit our Team Page at: https://www.no-shave.org/team/TeamThompson - We’re at just over 50% of our goal of $1500 for the month. Your support would inspire us to the finish line. Thank you!

Thursday, November 12, 2015

Great Day at the IAC Mid-Year Convention


We're reminding our P&C Partners (of which there are many) that we are here to help them grow their businesses and retention rates. 

Adam Thompson
SVP - Business
Development

We do this with customized automated marketing campaigns on behalf of our P&C Partners, offering additional coverages to your Personal Lines clients. 

Rounding your accounts can do wonders for retention and revenues.

Life Insurance is the main thrust of these campaigns because that's what we do, but also because most Personal Lines clients don't know you offer it... and because Life Insurance represents less than 2% of revenues for Independent Agencies. So we help you tell your existing customers you can do it and how to go about it.

Brian Thompson
Vice President
Sales
Up-selling existing customers is the most efficient way to grow. They already know and trust you with their protection needs. 

We are leading the way in coaching Independent Agencies in developing alternative revenue streams by leveraging existing client relationships. If you're interested in boosting your retention, and bottom line let's get together and make a plan to make it happen.


Take the next step >>


P.S. You wouldn't go to the store for apples if you have an orchard in your back yard.